Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

GenScript raises Life Science guidance as AI-driven demand drives strong revenue and margin gains

GenScript reported revenue growth of 27.3% and record adjusted net profit growth of over 200%, driven by surging AI-driven drug discovery (AIDD) demand and gains from automation. Management raised Life Science full-year revenue guidance to 25–30% and expects AIDD orders to double in H2 2026, while targeting positive EBITDA for the ProBio CDMO segment by 2027. The company plans about USD 130 million in 2026 capex to expand throughput, cites industry-leading 4‑day gene-to-protein turnaround in many labs, and holds roughly USD 830 million in cash; prior-period figures were adjusted to exclude the Renova license effect. » More on finance.yahoo.com
GenScript Biotech boosts profit in H1 2026 thanks to demand from AI-supported drug discovery

GenScript reported H1 2026 revenue of HKD 404.2 million (+27.3%) and adjusted net profit of HKD 62.5 million (+203.3%). Drivers were strong demand in life sciences and CDMO as well as growing AIDD orders, prompting management to raise full-year guidance for both business lines. The company saw improved margins and operating leverage, plans around USD 130 million in capex for 2026 and holds roughly USD 830 million in cash. The stock fell 4.23% after the results but remained close to its 52-week high. » More on de.investing.com
GenScript faces renewed US congressional scrutiny over China ties

US lawmakers have again raised concerns about GenScript Biotechnology's connections to China and its work with US companies, citing potential risks to US intellectual property. The House committee on China requested updated intelligence from the FBI and national intelligence directors regarding GenScript and its affiliates. GenScript, which operates in both the US and China, has previously denied taking direction from any government. » More on yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2017, Genscript Biotech has already paid €0.00115 in dividends. The last payout was in June 2017.

Financials

In the last quarter, Genscript Biotech had revenue of €353.33m and net profit of -€113.06m

(EUR)	June 2026	YoY
Revenue	353.33m	-
Gross profit	180.69m	-
Net profit	-113.06m	-
EBITDA	78.73m	-

Fundamentals

Metric	Value
Market capitalization	€8.07bn
Number of shares	2.25bn
52-week high/low	€5.62 - €1.18
Dividends	No
Beta	0.98
P/E ratio	-13.50
PEG ratio	0.00
P/B ratio	2.27
P/S ratio	10.74

Company profile

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.